Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2374-4677
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study ; volume:8 ; number:1 ; day:5 ; month:11 ; year:2022 ; pages:1-8 ; date:12.2022
npj Breast cancer ; 8, Heft 1 (5.11.2022), 1-8, 12.2022
- Creator
-
Rugo, Hope S.
Kabos, Peter
Beck, J. Thad
Jerusalem, Guy
Wildiers, Hans
Sevillano, Elena
Paz-Ares, Luis
Chisamore, Michael J.
Chapman, Sonya C.
Hossain, Anwar M.
Chen, Yanyun
Tolaney, Sara M.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41523-022-00482-2
- URN
-
urn:nbn:de:101:1-2023012022061154432002
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Rugo, Hope S.
- Kabos, Peter
- Beck, J. Thad
- Jerusalem, Guy
- Wildiers, Hans
- Sevillano, Elena
- Paz-Ares, Luis
- Chisamore, Michael J.
- Chapman, Sonya C.
- Hossain, Anwar M.
- Chen, Yanyun
- Tolaney, Sara M.
- SpringerLink (Online service)
Other Objects (12)
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial
Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
Objective Responses in Metastatic Pleomorphic Rhabdomyosarcoma Treated with Combination of Doxorubicin and Pembrolizumab: A Case Series
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study
Pembrolizumab as first-line treatment for metastatic uveal melanoma
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors
Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report
Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study
KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab
Pembrolizumab
Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial
Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
Objective Responses in Metastatic Pleomorphic Rhabdomyosarcoma Treated with Combination of Doxorubicin and Pembrolizumab: A Case Series
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study
Pembrolizumab as first-line treatment for metastatic uveal melanoma
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors
Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report
Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study
KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab
Pembrolizumab
Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial
Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
Objective Responses in Metastatic Pleomorphic Rhabdomyosarcoma Treated with Combination of Doxorubicin and Pembrolizumab: A Case Series
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study
Pembrolizumab as first-line treatment for metastatic uveal melanoma
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors
Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report
Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study
KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab
Pembrolizumab